This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robbins, R. J. Articles by Tuttle, R. M. Search for Related Content PubMed PubMed Citation Articles by Robbins, R. J. Articles by Tuttle, R. M.

Factors Influencing the Basal and Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin in Patients with Metastatic Thyroid Carcinoma

Endocrinology, Head and Neck Surgery, Molecular Pathology, Nuclear Medicine, and Clinical Chemistry Services, Departments of Medicine, Surgery, Pathology, Radiology, and Clinical Laboratories, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Address all correspondence and requests for reprints to: Dr. Richard J. Robbins, Endocrine Service, Box 296, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021. E-mail: robbinsr{at}mskcc.org.

The serum thyroglobulin (Tg) level is the most sensitive marker for detecting residual thyroid carcinoma. We hypothesized that the basal and TSH-stimulated Tg levels in patients with metastatic thyroid carcinoma would reflect tumor volume, histological subtype, and location of metastatic lesions. A retrospective review of 417 thyroid cancer survivors undergoing evaluation for residual disease with the assistance of recombinant human TSH (rhTSH) was performed. In 169 patients with metastatic disease, we found that the basal Tg level directly correlated with the number of lesions, and that it was highest in patients with follicular and lowest in those with papillary thyroid carcinoma. The basal Tg level was highest in patients with bone metastases and lowest in those with cervical metastases. The fold increase in the serum Tg after rhTSH treatment was highest in papillary thyroid carcinoma and lowest in Hurthle cell carcinoma. The fold increase in Tg was not influenced by tumor volume or by the site of metastatic lesions. Multivariate analysis showed multiple interactions between factors, but did not identify one factor that significantly influenced basal Tg or fold increase. We conclude that the location and volume of metastases influence basal Tg, but not its responsiveness to rhTSH, whereas the histological type of carcinoma influences both basal Tg and responsiveness to rhTSH.

This article has been cited by other articles:

				R. M. Tuttle, M. Brokhin, G. Omry, A. J. Martorella, S. M. Larson, R. K. Grewal, M. Fleisher, and R. J. Robbins Recombinant Human TSH-Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal J. Nucl. Med., May 1, 2008; 49(5): 764 - 770. [Abstract] [Full Text] [PDF]

				J. Villanueva, A. J. Martorella, K. Lawlor, J. Philip, M. Fleisher, R. J. Robbins, and P. Tempst Serum Peptidome Patterns That Distinguish Metastatic Thyroid Carcinoma from Cancer-free Controls Are Unbiased by Gender and Age Mol. Cell. Proteomics, October 1, 2006; 5(10): 1840 - 1852. [Abstract] [Full Text] [PDF]

				D. A. Pryma, H. Schoder, M. Gonen, R. J. Robbins, S. M. Larson, and H. W.D. Yeung Diagnostic Accuracy and Prognostic Value of 18F-FDG PET in Hurthle Cell Thyroid Cancer Patients J. Nucl. Med., August 1, 2006; 47(8): 1260 - 1266. [Abstract] [Full Text] [PDF]